Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users
Shram, M J, Schoedel, K A, Bartlett, C, Shazer, R L, Anderson, C M, Sellers, E M
Published in Clinical pharmacology and therapeutics (01.05.2011)
Published in Clinical pharmacology and therapeutics (01.05.2011)
Get more information
Journal Article
30LBA A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors
Rosen, L.S, Wesolowski, R, Gibson, B, Baffa, R, Liao, K.H, Masters, J, Hua, S.Y, Deng, S, Shazer, R, Tolcher, A.W
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Leal, T.A., Berz, D., Rybkin, I., Iams, W.T., Bruno, D., Blakely, C., Spira, A., Patel, M., Waterhouse, D.M., Richards, D., Pham, A., Jotte, R., Garon, E.B., Hong, D.S., Shazer, R., Yan, X., Latven, L., He, K.
Published in Annals of oncology (01.03.2022)
Published in Annals of oncology (01.03.2022)
Get full text
Journal Article
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H, de Marinis, F, Dumoulin, D, Reynolds, C, Theelen, W S M E, Percent, I, Gutierrez Calderon, V, Johnson, M L, Madroszyk-Flandin, A, Garon, E B, He, K, Planchard, D, Reck, M, Popat, S, Herbst, R S, Leal, T A, Shazer, R L, Yan, X, Harrigan, R, Peters, S
Published in Annals of oncology (01.01.2024)
Published in Annals of oncology (01.01.2024)
Get full text
Journal Article
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Leal, T.A., Berz, D., Rybkin, I., Iams, W.T., Bruno, D., Blakely, C., Spira, A., Patel, M.R., Waterhouse, D.M., Richards, D., Pham, A., Jotte, R., Garon, E.B., Hong, D., Shazer, R., Yan, X., Latven, L., He, K.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
Msaouel, P., Siefker-Radtke, A.O., Sweis, R., Mao, S., Rosenberg, J.E., Vaishampayan, U.N., Kalebasty, A. Rezazadeh, Pili, R., Bupathi, M., Nordquist, L.T., Shaffer, D.R., Davis, N., Zhang, T., Gandhi, S., Christensen, J., Shazer, R., Yan, X., Winter, M., Der-Torossian, H., Iyer, G. Vasudeva
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
Choueiri, T., Agarwal, N., Ho, T., Pal, S.K., Seon, B., Jivani, M., Adams, B., Shazer, R., Theuer, C.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)
Choueiri, T., Michaelson, M.D., Posadas, E., Sonpavde, G., McDermott, D., Seon, B., Jivani, M., Shazer, R., Adams, B., Theuer, C.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article
PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY)
Zhu, J., Song, Y., Smith, S.D., O'Connor, O.A., Luo, W., Shazer, R.L., Zhang, L., Han, I., Jivani, M.A., Liu, Y., Nowakowski, G.S.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
LoRusso, P., Markman, B., Tabernero, J., Shazer, R., Nguyen, L., Heath, E., Patnaik, A., Papadopoulos, K.
Published in Journal of clinical oncology (20.05.2009)
Published in Journal of clinical oncology (20.05.2009)
Get full text
Journal Article
Biomarkers and obesity in surgically treated patients with prostate cancer
Shazer, R., Bharne, A., Nepomuceno, E., Mirocha, J., Ramirez, C., Luthringer, D., Holden, S., Agus, D. B., Gross, M.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Obesity, ethnicity, and surgical outcomes for clinically localized prostate cancer
Gross, M., Jo, S., Huang, D., Mirocha, J., Shazer, R., Holden, S., Agus, D.
Published in Journal of clinical oncology (01.06.2005)
Published in Journal of clinical oncology (01.06.2005)
Get full text
Journal Article
Raloxifene, an oestrogen‐receptor‐β‐targeted therapy, inhibits androgen‐independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial
SHAZER, RONALD L., JAIN, ANJALI, GALKIN, ANNA V., CINMAN, NADYA, NGUYEN, KOO N., NATALE, RONALD B., GROSS, MITCHELL, GREEN, LELAND, BENDER, LEON I., HOLDEN, STUART, KAPLAN, LESLIE, AGUS, DAVID B.
Published in BJU international (01.04.2006)
Published in BJU international (01.04.2006)
Get full text
Journal Article